1-{2-[6-(3-hydroxyphenyl)-2-morpholin-4-ylpurin-9-yl]ethyl}-4-(methylsulfonyl)piperazine | 1138158-90-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 1-{2-[6-(3-hydroxyphenyl)-2-morpholin-4-ylpurin-9-yl]ethyl}-4-(methylsulfonyl)piperazine
• 英文别名: 3-[9-[2-(4-Methylsulfonylpiperazin-1-yl)ethyl]-2-morpholin-4-ylpurin-6-yl]phenol
• CAS: 1138158-90-3
• 化学式: C₂₂H₂₉N₇O₄S
• 分子量: 487.583
• InChiKey: IYIZFBZPZNGSBO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  34
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  125
• 氢给体数：
  1
• 氢受体数：
  10

文献信息

• P13K ISOFORM SELECTIVE INHIBITORS
  申请人：Liang Congxin

  公开号：US20110130395A1

  公开（公告）日：2011-06-02

  2-Morpholin-4-yl-9H-purine and 5-Morpholin-4-yl-3H-[1,2,3]triazolo[4,5-d]pyrimidine derivatives, especially those substituted by 6-heteroaryl, are unexpected PI3 kinase isoform selective inhibitors with good drug properties and are useful in treating disorders related to abnormal PI3K activities such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders.

  2-吗啡啉-4-基-9H-嘌呤和5-吗啡啉-4-基-3H-[1,2,3]三唑[4,5-d]嘧啶衍生物，特别是那些被6-杂环芳基取代的衍生物，是意外的PI3K酶亚型选择性抑制剂，具有良好的药物特性，并可用于治疗与异常PI3K活性相关的疾病，如癌症、免疫障碍、心血管疾病、病毒感染、炎症、代谢/内分泌障碍和神经系统疾病。
• 2-MORPHOLINYLPURINES AS INHIBITORS OF PI3K
  申请人：Nagaraj Harish Kumar Mysore

  公开号：US20110009403A1

  公开（公告）日：2011-01-13

  The present invention relates to purine compounds that are useful as kinase inhibitors. More particularly, the present invention relates to purine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative disorders. These compounds may be useful as medicaments for the treatment of a number of proliferative disorders including tumours and cancers as well as other disorders or conditions related to or associated with mTOR kinases.

  本发明涉及嘌呤化合物，可用作激酶抑制剂。更具体地说，本发明涉及嘌呤化合物、其制备方法、含有这些化合物的药物组合物以及这些化合物在治疗增殖性疾病方面的用途。这些化合物可以作为药物治疗多种增殖性疾病，包括肿瘤和癌症以及与mTOR激酶相关或相关的其他疾病或病况。
• PI3K ISOFORM SELECTIVE INHIBITORS
  申请人：Xcovery Holding Company LLC

  公开号：EP2307414A2

  公开（公告）日：2011-04-13
• US8513221B2
  申请人：——

  公开号：US8513221B2

  公开（公告）日：2013-08-20
• [EN] PI3K ISOFORM SELECTIVE INHIBITORS<br/>[FR] INHIBITEURS SÉLECTIFS DES ISOFORMES DE LA PI3 KINASE
  申请人：XCOVERY INC

  公开号：WO2010005558A2

  公开（公告）日：2010-01-14

  2-Morpholin-4-yl-9H-purine and 5-Morpholin-4-yl-3H-[ 1,2,3]triazolo[4,5-d] pyrimidine derivatives, especially those substituted by 6-heteroaryl, are unexpected PI3 kinase isoform selective inhibitors with good drug properties and are useful in treating disorders related to abnormal PI3K activities such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders.